Gujarat Magazine

DelveInsight’s “Pancreatic Cancer Pipeline Insight, 2025,” report provides comprehensive insights about 170+ companies and 200+ pipeline drugs in Pthe ancreatic Cancer pipeline landscape. It covers the Pancreatic Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pancreatic Cancer Pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Pancreatic Cancer Pipeline Report to explore emerging therapies, key Pancreatic Cancer Companies, and future Pancreatic Cancer treatment landscapes @ Pancreatic Cancer Pipeline Outlook Report

Key Takeaways from the Pancreatic Cancer Pipeline Report

• In June 2025, Exelixis announced a study to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
• In June 2025, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins conducted a study is to determine the optimal dose of AGEN2373 that is safe when given in combination with balstilimab and Pancreatic GVAX Whole Cell Vaccine and evaluate the safety and clinical activity of balstilimab and AGEN2373 in combination with GVAX (Arm 1) or mKRASvax (Arm 2) in surgically resectable pancreatic adenocarcinoma.
• In June 2025, Verastem Inc. organized a study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma (PDAC) who have been previously untreated.
• DelveInsight’s Pancreatic Cancer pipeline report depicts a robust space with 170+ active players working to develop 200+ pipeline therapies for Pancreatic Cancer treatment.
• The leading Pancreatic Cancer Companies such as Fibrogen, AB Science, Eleison Pharmaceuticals LLC, Janssen Pharmaceuticals, CARsgen Therapeutics, Arcus Biosciences, Inc., Chia Tai Tianqing Pharmaceutical Group, Innovent Biologics, Amgen, Biomea Fusion, Prestige Biopharma Limited, Bristol-Myers Squibb, GlaxoSmithKline, Incyte Corporation, Helix BioPharma, Genentech, Inc., ENB Therapeutics, Carrick Therapeutics, Avenge Bio, DEKA Biosciences, Keymed Biosciences, Pfizer, Redx Pharma Plc, and AIM ImmunoTech Inc., and others.
• Promising Pancreatic Cancer Pipeline Therapies such as Gemcitabine plus TS-1, Gemcitabine, FOLFOX, Nanoplatin (NC-6004), and Gemcitabine, and others.

Stay ahead with the most recent pipeline outlook for Pancreatic Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Pancreatic Cancer Treatment Drugs

Pancreatic Cancer Emerging Drugs Profile

• Pamrevlumab: FibroGen

Pamrevlumab is a potential first-in-class antibody being developed by FibroGen that inhibit the activity of connective tissue growth factor (CTGF), a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. The U.S. Food and Drug Administration has granted Orphan Drug Designation, and Fast Track designation to Pamrevlumab for the treatment of patients with pancreatic cancer. Currently it is in Phase III stage of clinical trial evaluation to treat Pancreatic Cancer.

• Masitinib: AB Science

Masitinib (AB-1010) is an investigational drug for the treatment of metastatic pancreatic cancer. The drug candidate is administered orally. It is an ATP-binding site competitor. The drug candidate acts by inhibiting wild-type forms of c-KIT, Fyn, Lyn tyrosine kinase and platelet-derived growth factor receptor alpha and beta. Masitinib is a selective inhibitor of the tyrosine kinase inhibitor that targets KIT. Currently being evaluated in the Phase III studies.

• Glufosfamide: Eleison Pharmaceuticals LLC.

Glufosfamide combines the active part of ifosfamide, a member of a widely used class of chemotherapy drugs called as alkylators with a glucose molecule. Because of its glucose component and a tumor cell’s increased need for glucose, glufosfamide may be preferentially transported into tumors compared to most normal tissues. Inside cells, the linkage between glucose and the alkylator is cleaved to release the active drug. Currently the drug is being evaluated in Phase III for the treatment of Pancreatic Cancer.

• Quemliclustat: Arcus Biosciences, Inc.

Quemliclustat is a potent and selective small molecule being developed by Arcus Biosciences. Inhibitor of CD73 that has been shown to block the production of adenosine. The reduction of adenosine restores immune function. The drug candidate is administered through intravenous and oral route. The drug candidate is currently in Phase III stage of clinical trial.

• CT041: CARsgen Therapeutics

CT041 is a potential first in class autologous chimeric antigen receptor CAR T-cell product candidate that targets the protein CLDN18.2. CT041 targets the treatment of CLDN18.2 positive solid tumors with a primary focus on pancreatic cancer. The drug candidate presently is in Phase II stage.

• DK210: DEKA Biosciences

DK210 (EGFR) is the first of several experimental therapeutics developed as part of Deka’s platform of molecules, which combines the cytokines full strength IL-2 and a high affinity IL-10. While IL-2 is known to be toxic, when coupled with IL-10, toxicity is not only reduced but its potency is increased, thereby creating a more tolerable and effective treatment for patients. It is the first of several experimental therapeutics in Deka’s platform of molecules which are being developed to treat both cancer and inflammatory diseases. These therapeutics, known as DiakinesTM, involve coupling two cytokines together onto a single chain variable fragment (scFv) targeting system to enhance their precision in targeting specific tissues. Furthermore, the scFv scaffold used in the DiakineTM platform also improves efficacy, safety and manufacturability of each treatment. The drug candidate presently is in Phase I stage for the treatment of pancreatic cancer.

• CT7001: Carrick Therapeutics

Samuraciclib is the most advanced CDK7 inhibitor in clinical development. Inhibiting CDK7 is a promising therapeutic strategy in cancer as CDK7 regulates the transcription of cancer-causing genes, promotes uncontrolled cell cycle progression and promotes resistance to anti-hormone therapy. Samuraciclib has demonstrated a favorable safety profile and encouraging efficacy in early clinical studies. In addition to the above studies, samuraciclib has further potential in prostate, pancreatic, ovarian and colorectal cancers. Samuraciclib has been granted Fast Track designation from the U.S. Food and Drug Administration (FDA) for use in combination with fulvestrant for the treatment of CDK4/6i resistant HR+, HER2- advanced breast cancer. Carrick is collaborating with Roche, Menarini Group and Arvinas/Pfizer to evaluate novel combinations of samuraciclib with Roche’s oral SERD giredestrant, Menarini Group’s oral SERD elacestrant, and Arvinas/Pfizer’s proteolysis targeting chimera (PROTAC) Estrogen Receptor degrader vepdegestrant (ARV-471) in late-stage CDK4/6i resistant HR+, HER2- metastatic breast cancer. Currently the drug is in preclinical stage of its development for the treatment of pancreatic cancer.

The Pancreatic Cancer Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Pancreatic Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pancreatic Cancer treatment.
• Pancreatic Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Pancreatic Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pancreatic Cancer market.

Explore groundbreaking therapies and clinical trials in the Pancreatic Cancer Pipeline. Access DelveInsight’s detailed report now! @ New Pancreatic Cancer Drugs

Pancreatic Cancer Companies

Fibrogen, AB Science, Eleison Pharmaceuticals LLC, Janssen Pharmaceuticals, CARsgen Therapeutics, Arcus Biosciences, Inc., Chia Tai Tianqing Pharmaceutical Group, Innovent Biologics, Amgen, Biomea Fusion, Prestige Biopharma Limited, Bristol-Myers Squibb, GlaxoSmithKline, Incyte Corporation, Helix BioPharma, Genentech, Inc., ENB Therapeutics, Carrick Therapeutics, Avenge Bio, DEKA Biosciences, Keymed Biosciences, Pfizer, Redx Pharma Plc, and AIM ImmunoTech Inc., and others

Pancreatic Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Pancreatic Cancer Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Unveil the future of Pancreatic Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Pancreatic Cancer Market Drivers and Barriers

Scope of the Pancreatic Cancer Pipeline Report

• Coverage- Global
• Pancreatic Cancer Companies- Fibrogen, AB Science, Eleison Pharmaceuticals LLC, Janssen Pharmaceuticals, CARsgen Therapeutics, Arcus Biosciences, Inc., Chia Tai Tianqing Pharmaceutical Group, Innovent Biologics, Amgen, Biomea Fusion, Prestige Biopharma Limited, Bristol-Myers Squibb, GlaxoSmithKline, Incyte Corporation, Helix BioPharma, Genentech, Inc., ENB Therapeutics, Carrick Therapeutics, Avenge Bio, DEKA Biosciences, Keymed Biosciences, Pfizer, Redx Pharma Plc, and AIM ImmunoTech Inc., and others.
• Pancreatic Cancer Pipeline Therapies- Gemcitabine plus TS-1, Gemcitabine, FOLFOX, Nanoplatin (NC-6004) and Gemcitabine, and others.
• Pancreatic Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Pancreatic Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Pancreatic Cancer drug development? Find out in DelveInsight’s exclusive Pancreatic Cancer Pipeline Report—access it now! @ Pancreatic Cancer Emerging Drugs and Major Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Pancreatic Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Pancreatic Cancer – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Pamrevlumab: FibroGen
9. Drug profiles in the detailed report…..
10. Mid-Stage Products (Phase II)
11. CT041: CARsgen Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. DK210: DEKA Biosciences
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Pancreatic Cancer Key Companies
21. Pancreatic Cancer Key Products
22. Pancreatic Cancer- Unmet Needs
23. Pancreatic Cancer- Market Drivers and Barriers
24. Pancreatic Cancer- Future Perspectives and Conclusion
25. Pancreatic Cancer Analyst Views
26. Pancreatic Cancer Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/pancreatic-cancer-pipeline-insight